Nirsevimab reduced respiratory syncytial virus infections and hospitalisations in preterm infants in Phase IIb trial

Nirsevimab showed a significant reduction in medically-attended lower respiratory tract infections (LRTI) and hospitalisations caused by respiratory syncytial virus (RSV) in healthy preterm infants in a positive Phase IIb trial published in the New England Journal of Medicine.
Läs mer